
Ta Hsung Tung
Examiner (ID: 4022)
| Most Active Art Unit | 1102 |
| Art Unit(s) | 1744, 1104, 1753, 1106, 1102, 1743, 2899, 2701, 2901 |
| Total Applications | 1660 |
| Issued Applications | 1317 |
| Pending Applications | 54 |
| Abandoned Applications | 289 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17726567
[patent_doc_number] => 11382932
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-12
[patent_title] => Genetically engineered hematopoietic stem cells and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/222855
[patent_app_country] => US
[patent_app_date] => 2021-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 67
[patent_figures_cnt] => 84
[patent_no_of_words] => 69455
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222855
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/222855 | Genetically engineered hematopoietic stem cells and uses thereof | Apr 4, 2021 | Issued |
Array
(
[id] => 19677084
[patent_doc_number] => 12188938
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Anti-VISTA antibodies and fragments
[patent_app_type] => utility
[patent_app_number] => 17/205193
[patent_app_country] => US
[patent_app_date] => 2021-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 108
[patent_no_of_words] => 25591
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17205193
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/205193 | Anti-VISTA antibodies and fragments | Mar 17, 2021 | Issued |
Array
(
[id] => 17356791
[patent_doc_number] => 20220017587
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10
[patent_app_type] => utility
[patent_app_number] => 17/199239
[patent_app_country] => US
[patent_app_date] => 2021-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18227
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17199239
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/199239 | Dual cytokine fusion proteins comprising IL-10 | Mar 10, 2021 | Issued |
Array
(
[id] => 18298241
[patent_doc_number] => 20230107927
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS
[patent_app_type] => utility
[patent_app_number] => 17/802663
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22201
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -81
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17802663
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/802663 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | Feb 25, 2021 | Pending |
Array
(
[id] => 18932320
[patent_doc_number] => 11884727
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-30
[patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
[patent_app_type] => utility
[patent_app_number] => 17/186960
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 68
[patent_no_of_words] => 23084
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 169
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17186960
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/186960 | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis | Feb 25, 2021 | Issued |
Array
(
[id] => 19372924
[patent_doc_number] => 12064463
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-20
[patent_title] => Vista antagonist and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/186199
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 16862
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17186199
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/186199 | Vista antagonist and methods of use | Feb 25, 2021 | Issued |
Array
(
[id] => 16915885
[patent_doc_number] => 20210188977
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Amyotrophic Lateral Sclerosis
[patent_app_type] => utility
[patent_app_number] => 17/187011
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 176
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187011
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/187011 | Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis | Feb 25, 2021 | Issued |
Array
(
[id] => 17052210
[patent_doc_number] => 20210261644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/186822
[patent_app_country] => US
[patent_app_date] => 2021-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14146
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17186822
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/186822 | PD-1-based vaccines against coronavirus infection | Feb 25, 2021 | Issued |
Array
(
[id] => 17342145
[patent_doc_number] => 20220008476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => GENETICALLY ENGINEERED HEMATOPOIETIC STEM CELLS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/176610
[patent_app_country] => US
[patent_app_date] => 2021-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69664
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176610
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/176610 | Genetically engineered hematopoietic stem cells and uses thereof | Feb 15, 2021 | Issued |
Array
(
[id] => 18582887
[patent_doc_number] => 20230265144
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => INTERLEUKIN 29 MUTANT PROTEIN
[patent_app_type] => utility
[patent_app_number] => 17/999884
[patent_app_country] => US
[patent_app_date] => 2021-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11386
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999884
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999884 | INTERLEUKIN 29 MUTANT PROTEIN | Feb 7, 2021 | Pending |
Array
(
[id] => 18980174
[patent_doc_number] => 11905334
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Anti-human VSIG4 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/169095
[patent_app_country] => US
[patent_app_date] => 2021-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 59
[patent_figures_cnt] => 70
[patent_no_of_words] => 15578
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17169095
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/169095 | Anti-human VSIG4 antibodies and uses thereof | Feb 4, 2021 | Issued |
Array
(
[id] => 17185245
[patent_doc_number] => 20210332130
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/165120
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165120
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165120 | BI-SPECIFIC ANTIBODIES AGAINST TIM-3 AND PD-1 FOR IMMUNOTHERAPY IN CHRONIC IMMUNE CONDITIONS | Feb 1, 2021 | Abandoned |
Array
(
[id] => 16915850
[patent_doc_number] => 20210188942
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/163257
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 122543
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17163257
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/163257 | CD80 variant immunomodulatory proteins and uses thereof | Jan 28, 2021 | Issued |
Array
(
[id] => 17104371
[patent_doc_number] => 11124567
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-21
[patent_title] => Anti-TREM2 antibodies and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/151006
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 51
[patent_no_of_words] => 33393
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17151006
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/151006 | Anti-TREM2 antibodies and methods of use thereof | Jan 14, 2021 | Issued |
Array
(
[id] => 19778531
[patent_doc_number] => 12227555
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-18
[patent_title] => Use of gene editing to generate universal TCR re-directed t cells for adoptive immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/147521
[patent_app_country] => US
[patent_app_date] => 2021-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 49
[patent_figures_cnt] => 52
[patent_no_of_words] => 52789
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147521
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/147521 | Use of gene editing to generate universal TCR re-directed t cells for adoptive immunotherapy | Jan 12, 2021 | Issued |
Array
(
[id] => 19360863
[patent_doc_number] => 20240262897
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => ANTIBODY, RELATED USE, PHARMACEUTICAL COMPOSITION INCLUDING METHOD FOR DIAGNOSING FUNGAL INFECTIONS, FUNGAL INFECTION DIAGNOSIS KIT AND METHOD FOR TREATING FUNGAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/796661
[patent_app_country] => US
[patent_app_date] => 2021-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18781
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17796661
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/796661 | ANTIBODY, RELATED USE, PHARMACEUTICAL COMPOSITION INCLUDING METHOD FOR DIAGNOSING FUNGAL INFECTIONS, FUNGAL INFECTION DIAGNOSIS KIT AND METHOD FOR TREATING FUNGAL INFECTIONS | Jan 11, 2021 | Pending |
Array
(
[id] => 16793005
[patent_doc_number] => 20210122822
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => HUMANIZED ANTIBODIES AGAINST C-KIT
[patent_app_type] => utility
[patent_app_number] => 17/137228
[patent_app_country] => US
[patent_app_date] => 2020-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9832
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17137228
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/137228 | Humanized antibodies against c-Kit | Dec 28, 2020 | Issued |
Array
(
[id] => 19273272
[patent_doc_number] => 12023379
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Immunostimulatory compositions, particles, and uses related thereto
[patent_app_type] => utility
[patent_app_number] => 17/132320
[patent_app_country] => US
[patent_app_date] => 2020-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 12
[patent_no_of_words] => 11135
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17132320
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/132320 | Immunostimulatory compositions, particles, and uses related thereto | Dec 22, 2020 | Issued |
Array
(
[id] => 18199611
[patent_doc_number] => 20230053131
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => ANTIBODIES TO CANINE INTERLEUKIN-4 RECEPTOR ALPHA
[patent_app_type] => utility
[patent_app_number] => 17/784835
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11254
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 153
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17784835
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/784835 | ANTIBODIES TO CANINE INTERLEUKIN-4 RECEPTOR ALPHA | Dec 17, 2020 | Pending |
| 17/110104 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 | Dec 1, 2020 | Abandoned |